Skip to main content
      RT @MaxKonigMD: VEXAS is more common than you think in men >50 #ACR22 https://t.co/z2T6nBoI9a

      Max Konig MaxKonigMD

      3 years 10 months ago
      VEXAS is more common than you think in men >50 #ACR22 https://t.co/z2T6nBoI9a
      RT @DrTrishHarkins: Yr in review #ACR22 @RheumNow
      🌟GLORIA 2 yr data:
      👉Pred 5mg OD vs PBO >65y/o RA

      ✅⬇️

      Patricia Harkins DrTrishHarkins

      3 years 10 months ago
      Yr in review #ACR22 @RheumNow 🌟GLORIA 2 yr data: 👉Pred 5mg OD vs PBO >65y/o RA ✅⬇️ disease activity (DAS28 -0.38) ✅⬇️ joint damage (sharp/van der heijde -1.7) ❌ 24% ⬆️ a/e “Weigh success in benefit and failure in harm 2 individualise use of low dose pred in RA >65y/o”
      RT @doctorRBC: CAR T cell therapy for treatment of lupus
      Small sample size of 5 pts, but improvement in all pts, 4 achie

      Robert B Chao, MD doctorRBC

      3 years 10 months ago
      CAR T cell therapy for treatment of lupus Small sample size of 5 pts, but improvement in all pts, 4 achieving SLEDAI =0 Note - cytokine release syndrome in 3 pts. Excellent overview of CAR T cell therapy and its complexity! @RheumNow #ACR22 https://t.co/3PP14tVudb
      RT @JulianSegan: MTX increases pegloticase efficacy in MIRROR trial. Similar safety too. Shame the cost of pegloticase i

      Julian Segan JulianSegan

      3 years 10 months ago
      MTX increases pegloticase efficacy in MIRROR trial. Similar safety too. Shame the cost of pegloticase is prohibitive in Australia... @RheumNow #ACR22 #yearinreview
      RT @ericdeinmd: Year in Review
      #ACR22
      Pegloticase and MTX now FDA approved co-administration for tophaceous gout to prev

      Eric Dein ericdeinmd

      3 years 10 months ago
      Year in Review #ACR22 Pegloticase and MTX now FDA approved co-administration for tophaceous gout to prevent anti-drug antibodies ⁦@RheumNow⁩ https://t.co/EPtOrjJqLd
      RT @doctorRBC: Preview of what is sure to be discussed more in detail later..
      MIRROR trial of MTX co-administration with

      Robert B Chao, MD doctorRBC

      3 years 10 months ago
      Preview of what is sure to be discussed more in detail later.. MIRROR trial of MTX co-administration with pegloticase in treatment of gout. MTX co-administration improved control of gout, reduced infusion reactions @RheumNow #ACR22 https://t.co/r0MEq1rkgO
      RT @AurelieRheumo: ACR year in review: a summary of latest FDA approvals in spondyloarthritis by C. Langford
      #ACRyearinr

      Aurelie Najm AurelieRheumo

      3 years 10 months ago
      ACR year in review: a summary of latest FDA approvals in spondyloarthritis by C. Langford #ACRyearinreview #ACR22 @RheumNow https://t.co/u5TyRdQM7L
      RT @KDAO2011: Dr. C Langford on #YearinReview: ORAL Surveillance noted NNH=16 in pts w/ASCVD compared to NNH 223 in pts

      TheDaoIndex KDAO2011

      3 years 10 months ago
      Dr. C Langford on #YearinReview: ORAL Surveillance noted NNH=16 in pts w/ASCVD compared to NNH 223 in pts w/o ASCVD. This led to FDA warning on all JAKi; how does not this apply to the new JAKi's? Discussion needed with patients when starting this class of drug #ACR22 @rheumnow https://t.co/XtJVap6yjh
      RT @bella_mehta: Year in review #ACR22
      IVIG received FDA approval for dermatomyositis in 2022!
      @RheumNow

      Bella Mehta bella_mehta

      3 years 10 months ago
      Year in review #ACR22 IVIG received FDA approval for dermatomyositis in 2022! @RheumNow
      RT @ericdeinmd: Year in Review #ACR22
      IVIG received FDA approval for adult dermatomyositis, shows benefit versus placebo

      Eric Dein ericdeinmd

      3 years 10 months ago
      Year in Review #ACR22 IVIG received FDA approval for adult dermatomyositis, shows benefit versus placebo First approved Rx for inflammatory myositis ⁦@RheumNow⁩ https://t.co/T6qVTQQdTp
      RT @EBRheum: Good rundown of the PRODERM trial, published @NEJM earlier this year and on my podcast (https://t.co/PzEDi

      Mike Putman EBRheum

      3 years 10 months ago
      Good rundown of the PRODERM trial, published @NEJM earlier this year and on my podcast (https://t.co/PzEDiBdJZn) a few eps back I disagree w/Dr. Langford re:role in therapy. I use IVIG first line for most all pts w/myositis, grateful for the FDA approval! #ACR22 @RheumNow https://t.co/BfHZm4Kl49
      RT @AurelieRheumo: Folle et al propose a neural network to differentiate RA+ & RA- vs PsA w/ AUROC 75% & 67% for

      Aurelie Najm AurelieRheumo

      3 years 10 months ago
      Folle et al propose a neural network to differentiate RA+ & RA- vs PsA w/ AUROC 75% & 67% for RA+ vs RA- in 5 distinct hands MRI sequences. Question: what was the performance of the rheumatologist or radiologist? https://t.co/93aZKPlKsO Abstr#0242 #ACR22 @Rheumnow https://t.co/uk2c3gbAOT
      RT @ericdeinmd: Year in Review #ACR22
      CAR T cells: deep depletion of CD19 leading to immune reset
      5 patients with active

      Eric Dein ericdeinmd

      3 years 10 months ago
      Year in Review #ACR22 CAR T cells: deep depletion of CD19 leading to immune reset 5 patients with active SLE Normalizations of complements, dsDNA Drug free remission 3 will mild immune reconstitution symptoms, 1 received tocilizumab @RheumNow
      RT @EBRheum: Nice chart w/JAKs/TYKs by drug and by cytokine pathways

      In reality there is a fair bit of crossover and "

      Mike Putman EBRheum

      3 years 10 months ago
      Nice chart w/JAKs/TYKs by drug and by cytokine pathways In reality there is a fair bit of crossover and "selectives" aren't nearly as selective as this implies Helpful to add deucravacitinib to the list! Looking forward to upcoming plenary #RheumNow #ACR22 #YearInReview https://t.co/MERzpvrFB9
      RT @vksandhumd: Nice summary slide of JAK inhibitors and the history of JAKi in rheumatology,
      #ACR22 #ACRambassador htt

      Vaneet K Sandhu, MD, RhMSUS (she/her) vksandhumd

      3 years 10 months ago
      Nice summary slide of JAK inhibitors and the history of JAKi in rheumatology, #ACR22 #ACRambassador https://t.co/Ij2D7YikjT
      ×